Pendulum Review: A Real Trial, and a Misleading Frame
Pendulum sells probiotics built around Akkermansia muciniphila, a gut bacterium that has become one of the most studied organisms in metabolic research. Its products run from about $30 to $74 a month and are HSA and FSA eligible. Two things make it unusual. It has a genuine double-blinded placebo-controlled trial published in a peer-reviewed journal behind its Glucose Control product — almost unheard of in the supplement aisle. And it sits at the centre of the natural GLP-1 marketing wave, which is where the care is needed.
Verified August 24, 2026. Pendulum is a supplement company, not a healthcare provider. Its products are not substitutes for prescribed medication. For weight-loss medication see our GLP-1 provider rankings.
Affiliate disclosure: Rx Saver Hub earns a commission if you sign up through links on this page. It does not change what we write — see our disclosure policy.
Verdict: The best-evidenced probiotic company on the market, sold into a moment that invites people to misread it. The Perraudeau trial published in BMJ Open Diabetes Research and Care is real: double-blinded, placebo-controlled, and reporting an average A1C reduction of 0.6 percentage points and a 32.5 percent reduction in post-meal glucose spikes in people with type 2 diabetes. That is a legitimate result. What it is not is a GLP-1 medication. Akkermansia does nudge your body's own GLP-1 secretion, but the gap between that and what semaglutide does is enormous, and marketing across this category blurs it.
What Pendulum Costs
Pendulum prices by product, monthly, with HSA and FSA funds accepted.
| Plan | What you get | Listed | Real cost |
|---|---|---|---|
| Metabolic Daily | 5-strain daily probiotic with live Akkermansia | $49/month | Flagship product |
| Akkermansia | Single keystone strain | $54/month | Gut lining and barrier focus |
| Glucose Control | The formulation with the published RCT | Around $74/month | Strongest evidence in the range |
| Entry products | Polyphenol Booster, Gut Fuel | From $30 | Adjuncts rather than the core |
A probiotic is not a GLP-1 medication
Akkermansia does stimulate your body's own GLP-1 secretion — that mechanism is real and documented. But endogenous GLP-1 released in response to a gut organism operates at a completely different scale from a weekly injection of semaglutide, which produces sustained receptor activation far above anything the body generates on its own. Anyone reading natural GLP-1 as an alternative to the prescription is misunderstanding the difference by orders of magnitude.
At around $74 a month, Glucose Control is expensive for a supplement — but it is the one in the range with an actual randomised controlled trial behind it, which is worth more than a cheaper product with none.
What the trial actually found
Perraudeau and colleagues published a double-blinded, placebo-controlled trial in BMJ Open Diabetes Research and Care in 2020. Participants taking the Pendulum formulation showed an average A1C reduction of 0.6 percentage points and a 32.5 percent reduction in post-meal glucose spikes compared with placebo.
That is a genuinely meaningful result for a supplement, and the study design — randomised, blinded, placebo-controlled, peer-reviewed — is what separates it from the testimonial-driven evidence most of the category runs on. Pendulum links the paper directly rather than gesturing at unnamed studies.
Two caveats matter for reading it correctly. The population was people living with type 2 diabetes, so it does not transfer automatically to someone without diabetes seeking weight loss. And the endpoints were glycaemic, not weight — the trial did not demonstrate weight loss.
Where Akkermansia and GLP-1 genuinely connect
Akkermansia muciniphila lives in the mucus layer of the gut and produces short-chain fatty acids that signal to enteroendocrine cells, which in turn release GLP-1 and other satiety hormones. Lower Akkermansia abundance is consistently associated with obesity and metabolic dysfunction in observational work.
This is a real mechanism, not marketing invention. But an association between an organism and a metabolic state does not establish that supplementing it produces the outcome — and the size of the endogenous GLP-1 signal involved is not remotely comparable to pharmacological dosing.
Where it could genuinely fit alongside a GLP-1
If there is a sensible use here, it is complementary rather than substitutive: someone already on semaglutide or tirzepatide, with type 2 diabetes or elevated A1C, whose clinician thinks the glycaemic data is worth acting on. That is a conversation to have with the person managing your diabetes.
The use that does not make sense is buying this instead of medication because the marketing said natural GLP-1. If you qualify for and can access a prescription GLP-1, that is a categorically different intervention.
What to check before buying
Confirm which product carries the evidence you are buying for. The published trial concerns the Glucose Control formulation specifically — not every product in the range, and not the single-strain Akkermansia on its own.
HSA and FSA eligibility is worth using here given the price, and Pendulum states it accepts those funds. If you have an account with a balance, that materially changes the effective cost.
Pros and Cons
Strengths
- Genuine double-blinded placebo-controlled RCT published in a peer-reviewed journal
- Links the study directly rather than citing vague unnamed research
- Live Akkermansia muciniphila, which is technically difficult to produce and deliver
- HSA and FSA eligible, materially reducing effective cost
- Names every strain in each formulation
Drawbacks
- Natural GLP-1 framing invites a false comparison with prescription medication
- The trial studied people with type 2 diabetes and glycaemic endpoints, not weight loss
- Around $74 a month for Glucose Control is expensive
- Evidence attaches to one specific formulation, not the whole range
- Dietary supplements are not FDA-reviewed for effectiveness before sale
Who Should Pick It — and Who Shouldn't
Good fit
Someone with type 2 diabetes or elevated A1C, ideally alongside rather than instead of prescribed treatment, who wants the one probiotic with a real randomised trial behind it and can use HSA or FSA funds.
Look elsewhere
Anyone reading natural GLP-1 as an alternative to semaglutide or tirzepatide. The mechanisms overlap; the magnitudes do not. If you qualify for the medication, this is not a substitute for it.
Frequently Asked Questions
Is Pendulum a natural GLP-1?
It stimulates your body's own GLP-1 secretion through Akkermansia and short-chain fatty acid signalling, which is a real mechanism. It is not comparable in magnitude to a GLP-1 medication, which produces sustained receptor activation far beyond anything the gut generates naturally.
Does Pendulum actually lower A1C?
A double-blinded placebo-controlled trial published in BMJ Open Diabetes Research and Care reported an average 0.6 percentage point A1C reduction and a 32.5 percent reduction in post-meal glucose spikes with the Glucose Control formulation, in people with type 2 diabetes. That is the specific claim the evidence supports.
Can I take Pendulum with semaglutide?
There is no known interaction, and someone with diabetes might reasonably use both — but ask the clinician managing your diabetes first, particularly if you are on glucose-lowering medication where an additional effect could matter for dosing.
How much does Pendulum cost?
Metabolic Daily is $49 a month, Akkermansia $54, and Glucose Control around $74, with entry products from $30. HSA and FSA funds are accepted, which meaningfully lowers the real cost if you have a balance.
Considering Pendulum?
Pendulum is the rare supplement with a real randomised trial behind it. Buy it for the glycaemic evidence it actually has — not as a natural substitute for a GLP-1 medication, which it is not.
More Reviews Like This
Other brands we have reviewed in the same category.
Pricing, strain lists and the cited trial read from pendulumlife.com on August 24, 2026 and subject to change. Trial reference: Perraudeau et al, BMJ Open Diabetes Research and Care, 2020. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Rx Saver Hub earns a commission on purchases made through links on this page.